Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Singulex, Inc.
Finance Watch: Rivus Raises $132m In Series B Cash To Fund Obesity Drug Trials
VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.
Finance Watch: $135m In Venture Capital Will Fund Amylyx’s Late-Stage ALS Drug
Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.
Inivata Names Clive Morris New CEO
Inivata's Chief Medical Officer Clive Morris will take over as CEO of the liquid biopsy company. Former CEO Michael Stocum departed earlier this year.
Singulex And Qiagen Partner In Personalized Medicine
Singulex and Qiagen have entered a strategic alliance whereby Qiagen will be able to offer its clients companion diagnostic development services based on Singulex’s Single Molecule Counting technology.
- Digital Health
- Diagnostic Imaging Services
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.